BioNano Genomics Inc (NASDAQ: BNGO) Visual Genome Charting discloses new Visions and Predictive Abilities

BioNano Genomics Inc (NASDAQ: BNGO) has announced that its visual genome charting has revealed its new visions and predictive abilities that it offered at the 2021 European Cytogenomics Conference (ECA). 

Summary of the leukemia demonstrations at the ECA containing OGM 

One of the climaxes from the session included Dr. Elena García Sánchez from the Hospital Infantil Universitario Niño Jesús. They offered a complete study displaying the worth of OGM for the analysis of pediatric leukemia. In this learning, 34 pediatric leukemias were examined by OGM compare to old-style methods (karyotyping, FISH, and PCR). 

The consequences of this study showed 100% concordance comparative to these usual methods, and in 60% of these cases, exposed new clinically pertinent info. This study is the basis of authentication and authorization of an assay to be expended onsite in their test center. The new info that OGM revealed could signify an opening for enhanced treatment opportunities, patient stratification, or restorative care. In addition, these conclusions exposed original gene fusion proceedings that are being discovered for prognostic submissions in cancer organizations.

WeHealth Shanghai embraces BioNano Genomics Saphyr® System for visual genome charting

In other news, BioNano Genomics has revealed that WeHealth Shanghai has adopted its Saphyr® System for visual genome charting. The company announced the acceptance at the Structural Variation Conference in Shanghai, planned with backing from the Shanghai Society of Genetics. In addition, WeHealth announced the presentation of its total genome-analysis contribution with OGM pooled with whole-exome or whole-genome sequencing.

The Structural Variation Conference also contained a series of technical demonstrations covering a varied range of submissions of OGM in genome investigation. In addition, manifold demonstrations were transported on reproductive fitness, a vital necessity, and opening in China with around 16 million births yearly.

Xiangdong Kong from The First Affiliated Hospital of Zhengzhou University used OGM for prenatal analysis in clans with a past of facioscapulohumeral muscular dystrophy (FSHD), a type of muscular dystrophy. Since the current standard of upkeep for FSHD examination uses an old-fashioned skill requiring amounts of DNA far superior to can be accumulated by amniocentesis, prenatal testing for FSHD has not happened in China. Expending OGM, Dr. Kong positively examined 12 prenatal examples for FSHD, demonstrating an opening to redefine the usual care in China concerning FSHD examination with OGM.

Leave a Comment

Your email address will not be published.